Tranzyme and B-MS extend their drug discovery collaboration

- Last updated on GMT

Related tags: Pharmacology, Bristol-myers squibb

Tranzyme Pharma has extended its drug discovery collaboration with Bristol-Myers Squibb.

Under the deal – first inked in December 2009 for a period of two years –Tranzyme provides its proprietary drug discovery technology, Macrocyclic Template Chemistry (MATCH), to identify candidates.

Bristol-Myers Squibb (B-MS) then completes the preclinical and clinical development of all products arising from the collaboration, and is responsible for their commercialisation.

The new agreement gives B-MS an additional six months, with the option to further extend the collaboration after June 2012.

North Carolina, US- based Tranzyme will continue to receive funding from its partner and is eligible for the same development and regulatory milestones and tiered royalties for each product resulting from the collaboration.

Excluding royalties, milestone payments under the agreement could reach up to $80m (€58m) for each target programme.

Related news

Related products

show more

What to consider when working with CRFs

What to consider when working with CRFs

Formedix | 01-Nov-2021 | Technical / White Paper

For a study to be successful, data collected must be correct and complete. To be correct and complete, forms must be well planned with meticulous attention...

Automating clinical trials for success

Automating clinical trials for success

Formedix | 06-Oct-2021 | Technical / White Paper

This article gives gives a brief overview of why automation is absolutely essential for clinical trial success.

What should a clinical metadata repository do?

What should a clinical metadata repository do?

Formedix | 26-Jul-2021 | Technical / White Paper

Choosing a clinical metadata repository (MDR) software can be a tough task as the capabilities and features of your chosen MDR could make or break your...

Related suppliers

Follow us

Products

View more

Webinars